Mangoceuticals (MGRX) Competitors

Mangoceuticals logo
$0.16 0.00 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$0.16 +0.00 (+1.25%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MGRX vs. ACH, GXAI, AIDX, IVF, and BIAF

Should you buy Mangoceuticals stock or one of its competitors? Mangoceuticals's main competitors and comparable companies include Accendra Health (ACH), Gaxos.ai (GXAI), 20/20 Biolabs (AIDX), INVO Fertility (IVF), and bioAffinity Technologies (BIAF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Mangoceuticals compare to Accendra Health?

Accendra Health (NYSE:ACH) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Mangoceuticals had 2 more articles in the media than Accendra Health. MarketBeat recorded 6 mentions for Mangoceuticals and 4 mentions for Accendra Health. Mangoceuticals' average media sentiment score of 0.19 beat Accendra Health's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Accendra Health
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mangoceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Accendra Health presently has a consensus target price of $1.50, indicating a potential upside of 1,650.29%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accendra Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Accendra Health has a net margin of -6.72% compared to Mangoceuticals' net margin of -4,794.60%. Accendra Health's return on equity of -4.02% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Accendra Health-6.72% -4.02% -0.83%
Mangoceuticals -4,794.60%-96.39%-89.60%

Accendra Health has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.15, suggesting that its share price is 115% more volatile than the broader market.

Mangoceuticals has lower revenue, but higher earnings than Accendra Health. Mangoceuticals is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accendra Health$2.73B0.00-$1.10B-$2.22N/A
Mangoceuticals$460K7.50-$20.64M-$1.01N/A

56.7% of Mangoceuticals shares are held by institutional investors. 0.6% of Accendra Health shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Mangoceuticals beats Accendra Health on 8 of the 15 factors compared between the two stocks.

How does Mangoceuticals compare to Gaxos.ai?

Mangoceuticals (NASDAQ:MGRX) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mangoceuticals had 2 more articles in the media than Gaxos.ai. MarketBeat recorded 6 mentions for Mangoceuticals and 4 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 1.15 beat Mangoceuticals' score of 0.19 indicating that Gaxos.ai is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mangoceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gaxos.ai
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mangoceuticals$460K7.50-$20.64M-$1.01N/A
Gaxos.ai$1.93M2.60-$3.90M-$0.44N/A

Mangoceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market. Comparatively, Gaxos.ai has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Gaxos.ai has a net margin of -46.46% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.01% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mangoceuticals-4,794.60% -96.39% -89.60%
Gaxos.ai -46.46%-38.01%-36.07%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Gaxos.ai beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to 20/20 Biolabs?

Mangoceuticals (NASDAQ:MGRX) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mangoceuticals$460K7.50-$20.64M-$1.01N/A
20/20 Biolabs$2.05M1.22-$3.74M-$0.54N/A

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mangoceuticals-4,794.60% -96.39% -89.60%
20/20 Biolabs N/A N/A N/A

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 2,568.09%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Mangoceuticals had 3 more articles in the media than 20/20 Biolabs. MarketBeat recorded 6 mentions for Mangoceuticals and 3 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.27 beat Mangoceuticals' score of 0.19 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mangoceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
20/20 Biolabs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 27.7% of 20/20 Biolabs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats Mangoceuticals on 11 of the 15 factors compared between the two stocks.

How does Mangoceuticals compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 0.4% of INVO Fertility shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Mangoceuticals has lower revenue, but higher earnings than INVO Fertility. Mangoceuticals is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$6.84M0.20-$25.13M-$135.32N/A
Mangoceuticals$460K7.50-$20.64M-$1.01N/A

INVO Fertility currently has a consensus target price of $320.00, suggesting a potential upside of 14,578.90%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts plainly believe INVO Fertility is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

INVO Fertility has a net margin of -116.29% compared to Mangoceuticals' net margin of -4,794.60%. INVO Fertility's return on equity of -85.54% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-116.29% -85.54% -31.05%
Mangoceuticals -4,794.60%-96.39%-89.60%

In the previous week, Mangoceuticals had 1 more articles in the media than INVO Fertility. MarketBeat recorded 6 mentions for Mangoceuticals and 5 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 0.37 beat Mangoceuticals' score of 0.19 indicating that INVO Fertility is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
INVO Fertility
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mangoceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

INVO Fertility has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market.

Summary

INVO Fertility beats Mangoceuticals on 10 of the 16 factors compared between the two stocks.

How does Mangoceuticals compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, bioAffinity Technologies and bioAffinity Technologies both had 6 articles in the media. Mangoceuticals' average media sentiment score of 0.19 beat bioAffinity Technologies' score of 0.12 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
bioAffinity Technologies
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mangoceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 2.4% of bioAffinity Technologies shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

bioAffinity Technologies has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the broader market.

bioAffinity Technologies has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M0.57-$14.91M-$44.27N/A
Mangoceuticals$460K7.50-$20.64M-$1.01N/A

bioAffinity Technologies has a net margin of -278.90% compared to Mangoceuticals' net margin of -4,794.60%. Mangoceuticals' return on equity of -96.39% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-278.90% -293.44% -160.36%
Mangoceuticals -4,794.60%-96.39%-89.60%

Summary

Mangoceuticals beats bioAffinity Technologies on 8 of the 12 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGRX vs. The Competition

MetricMangoceuticalsHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.45M$10.57B$7.74B$11.66B
Dividend YieldN/A2.54%2.46%4.42%
P/E Ratio-0.1635.8034.1729.85
Price / Sales7.502.088.485.62
Price / CashN/A23.3421.9322.50
Price / Book0.173.594.373.66
Net Income-$20.64M$332.46M$3.52B$392.18M
7 Day Performance-15.43%-3.97%-5.43%-4.29%
1 Month Performance-44.81%-1.73%-4.54%-6.78%
1 Year Performance-87.30%19.12%-1.40%-7.10%

Mangoceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGRX
Mangoceuticals
1.0677 of 5 stars
$0.16
-0.2%
N/A-89.2%$3.45M$460KN/A3
ACH
Accendra Health
1.4246 of 5 stars
$0.13
-11.7%
$1.50
+1,063.7%
N/A$9.92M$2.73BN/A6,500
GXAI
Gaxos.ai
1.1686 of 5 stars
$0.43
+1.7%
N/A-66.7%$4.62M$1.93MN/A3
AIDX
20/20 Biolabs
1.8061 of 5 stars
$0.20
-0.9%
$5.00
+2,375.2%
N/A$2.70M$2.05MN/A14
IVF
INVO Fertility
2.9654 of 5 stars
$2.62
-2.4%
$320.00
+12,137.1%
-99.2%$1.65M$6.84MN/A46

Related Companies and Tools


This page (NASDAQ:MGRX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners